Neumora Therapeutics Inc (NASDAQ: NMRA) is a clinical-stage biopharmaceutical company that develops drug candidates targeting neurological and psychiatric disorders. The company generates no product revenue, funding operations entirely through equity financing and debt facilities, including a Loan and Security Agreement with K2 HealthVentures LLC entered May 9, 2025 and amended twice through December 2025. Neumora has licensed assets from Amgen Inc under exclusive agreements covering targets including CK1d and GCase, and acquired additional pipeline assets through transactions such as the merger with BlackThorn Therapeutics Inc in 2020. Net cash used in operating activities was $206.4 million for the twelve months ended December 31, 2025, against a net loss of $236.9 million for the same period. The company competes with both large pharmaceutical companies and early-stage biotechs for clinical trial sites, scientific personnel, and complementary technologies. As of the 10-K filed March 30, 2026, Neumora had not received regulatory approval for any product candidate.

Revenue model

No product revenue as of the 10-K filed March 30, 2026. Operations are funded through equity and debt financing. Future revenue, if any, would come from product sales, milestones, royalties, and sublicensing under existing license and collaboration agreements, contingent on regulatory approvals.

Products and services

Clinical-stage drug candidates targeting neurological and psychiatric disorders, including licensed assets for CK1d and GCase targets (licensed from Amgen Inc, September 2021). Pipeline also includes assets acquired via merger with BlackThorn Therapeutics Inc (June 2020).

Customers and end markets

No commercial customers as of the 10-K filed March 30, 2026. End markets, if products are approved, would include patients with neurological and psychiatric conditions, with reimbursement exposure to Medicaid and other payers.

Value-chain role

Drug developer and licensor. Acquires and licenses early-stage assets, conducts preclinical studies and clinical trials using third-party contract research organizations and service providers, and is obligated under license agreements to use commercially reasonable efforts to advance specific programs.

Geographic exposure

Primarily United States-based operations. Clinical programs may extend into the European Economic Area, implicating GDPR compliance obligations.

Competitors

Large established pharmaceutical companies (unnamed in filing), Early-stage biopharmaceutical companies (unnamed in filing)

Source: SEC 10-K, filed 2026-03-30

Industry: Biological Products, (No Diagnostic Substances) Peers: Amneal Pharmaceuticals Inc Amphastar Pharmaceuticals, Inc. Arvinas Inc CymaBay Therapeutics, Inc. Eli Lilly and Co Harmony Biosciences Holdings Inc